Alkermes plc (FRA:8AK)

Market Cap	4.71B +3.1%
Revenue (ttm)	1.30B +1.1%
Net Income	288.78M +1.6%
EPS	1.72 +2.4%
Shares Out	n/a
PE Ratio	16.31
Forward PE	19.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1
Open	27.60
Previous Close	27.40
Day's Range	27.60 - 27.60
52-Week Range	22.00 - 34.60
Beta	n/a
RSI	68.80
Earnings Date	Feb 13, 2026

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable su...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 1,800
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8AK

Financial Performance

In 2024, Alkermes's revenue was $1.56 billion, a decrease of -6.36% compared to the previous year's $1.66 billion. Earnings were $367.07 million, an increase of 3.18%.

Financial numbers in USD